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Integrase (IN) is a retroviral enzyme that catalyzes the insertion of viral DNA (vDNA) into
host chromosomal DNA, which is necessary for efﬁcient viral replication.The crystal struc-
ture of prototype foamy virus IN bound to cognate vDNA ends, a complex referred to as
the intasome, has recently been resolved. Structure analysis of the intasome revealed a
tetramer structure of IN that was required for its catalytic function, and also showed the
inhibitory mechanism of the IN inhibitor. Genetic analysis of IN has revealed additional
non-enzymatic roles during viral replication cycles at several steps other than integration.
However, the higher order structure of IN that is required for its non-enzymatic functions
remains to be delineated. This is the next major challenge in the ﬁeld of IN structural biol-
ogy hoping to be a platform for the development of novel IN inhibitors to treat human
immunodeﬁciency virus type 1 infectious disease.
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INTRODUCTION
Reverse transcription of viral RNA into double-stranded (ds)
DNA, and the subsequent insertion of the synthesized viral DNA
(vDNA) into a host chromosome, are characteristic features of
retroviruses including human immunodeﬁciency virus type 1
(HIV-1). The reverse transcription and integration of the viral
genome is sequentially catalyzed by the enzymes reverse tran-
scriptase (RT) and integrase (IN), respectively. These retroviral
enzymes are originally packaged in the viral particle along with
the viral genomic RNA. After synthesis of vDNA by RT, IN acts on
the termini of vDNA and catalyzes insertion of the vDNA into
the host chromosome through two sequential enzymatic reac-
tions: 3′-end processing and strand-transfer (Katz and Skalka,
1994). Currently, a clinically approved IN inhibitor speciﬁcally
targets strand-transfer activity but not 3′-end processing activity
(Summa et al., 2008). Therefore, the IN inhibitor is referred to
as a strand-transfer inhibitor (STI). The STI shows very potent
antiviral activity; however, emergence of STI-resistant variants is
inevitable (Metiﬁot et al., 2010), as seen in patients treated with
a combination of inhibitors against RT and protease activities.
Efforts to developnovel drugswith distinct inhibitorymechanisms
must continue so that we can effectively treatHIV-1 infections. For
development of novel IN inhibitors, in addition to its enzymatic
action, other non-enzymatic functions of IN, as described below,
might be the next target(s) (Luo and Muesing, 2010).
STRUCTURE OF HIV-1 IN
Human immunodeﬁciency virus type 1 IN is composed of 288
amino acids with three structurally distinct domains (Li et al.,
2011): an N-terminal domain (NTD), a central catalytic core
domain (CCD), and a C-terminal domain (CTD; Figure 1).
The NTD contains a highly conserved (His-His-Cys-Cys, HHCC)
motif,which binds to zinc ions (Zn2+) and folds a helix-turn-helix
(HTH) structure. Through a tetrahedral attachment to the HHCC
motif, Zn2+ enhances both multimerization and enzymatic activ-
ities of HIV-1 IN in vitro (Burke et al., 1992; Ellison et al., 1995;
Cai et al., 1997). The CCD contains the highly conserved Asp,Asp,
and Glu (DDE) residues directly involved in the catalytic activ-
ities of IN (Engelman and Craigie, 1992; Kulkosky et al., 1992;
LaFemina et al., 1992; Bushman et al., 1993). Overall topology
of the CCD is similar to those of ribonuclease H (RNaseH), the
Holliday junction resolvase RuvC, and bacteriophage transposase
Mu. Despite lack of sequence similarity between the CCD and
RNaseH, there is remarkable similarity in the positioning of the
two Asp catalytic residues (Dyda et al., 1994). The CTD, consist-
ing of a structure that closely resembles Src homology 3 domains
(SH3-like), possesses sequence- and metal ion-independent DNA
binding activity (Eijkelenboom et al., 1995; Lodi et al., 1995). Each
domain has been demonstrated to form a dimer and higher mul-
timerization states (Dyda et al., 1994; Eijkelenboom et al., 1995;
Cai et al., 1997), which might be required for all the enzymatic
functions of IN.
Recently, the entire prototype foamy virus (PFV) IN in a com-
plex with its cognate vDNA ends, referred to as the intasome,
has been successfully crystallized (Hare et al., 2010). The crystal
structure analysis of the PFV intasome revealed an unprecedented
tetramer structure for IN (see Cherepanov et al., 2011; Li et al.,
2011 for recent review). The IN tetramer structure observed in the
PFV intasome demonstrated that two sets of IN dimer acts on each
vDNAend (Figure 2). The inner subunits of each INdimer contact
with vDNA and form a tetramer. The outer subunits of each IN
dimer might be speculated to have supportive or other functions,
such as engagement of target DNA or interaction with host fac-
tors. Several models for the IN tetramer have been proposed from
previous structure analysis using partial IN fragments possessing
theNTD–CCDor CCD–CTD (Chen et al., 2000;Wang et al., 2001;
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FIGURE 1 | Schematic diagram of HIV-1 IN.The genetic organization of HIV-1
is shown at the top. HIV-1 IN is encoded by the pol region and composed of
288 amino acids with three structurally distinct domains: an N-terminal domain
(NTD); a central catalytic core domain (CCD); and a C-terminal domain (CTD).
The CCD contains the highly conserved DDE motif, which is directly involved
in the catalytic activities of IN. Overall topology of the CCD is similar to that of
ribonuclease H (RNaseH). The NTD, contains a highly conserved HHCC motif,
which binds to zinc and folds a helix-turn-helix (HTH) structure. The CTD,
consisting of a structure that closely resembles Src homology 3 domains
(SH3), possesses sequence- and metal ion-independent DNA binding activity.
Hare et al., 2009a).However, these IN tetramermodels are different
from those observed in the active PFV intasome (Craigie, 2010).
Stable interaction of IN with 3′-end processed vDNA in the inta-
somemight be aplausible explanation for thedifference. The stable
IN tetramer formation observed in the intasome reﬂects the IN-
DNA complex required for proper concerted integration of both
vDNA ends into the proximal sites of the target host chromoso-
mal DNA. Furthermore, analysis of the PFV intasome interacting
with the STI elucidated its inhibitory mechanism. Based on the
PFV intasome structure as a template, structural modeling of the
HIV-1 intasome has also been reported (Krishnan et al., 2010).
Structural analysis of this intasome revealed numerous details of
retroviral integration and will contribute to the design of the next
generation of HIV-1 IN catalytic inhibitors. The functional signiﬁ-
cance of theDNA-independent IN tetramer as observedby analysis
of partial IN fragments (Chen et al., 2000; Wang et al., 2001; Hare
et al., 2009a) remains unclear (Cherepanov et al., 2011).
NON-ENZYMATIC FUNCTIONS OF IN
Originally,we found that introduction of amino acid substitutions
at conserved HHCC residues in the NTD of HIV-1 IN resulted in
almost complete abrogation of proviralDNA formation, concomi-
tant with a severe reduction in vDNA synthesis. This suggests the
mutations in the IN affected the viral life cycle at steps prior to
integration (Masuda et al., 1995). Further genetic analysis of HIV-
1 IN revealed that the pleiotropic effects of IN mutations affected
uncoating (Masuda et al., 1995; Leavitt et al., 1996; Nakamura
et al., 1997; Briones et al., 2010), reverse transcription (Engelman
et al., 1995; Masuda et al., 1995; Wu et al., 1999; Tsurutani et al.,
2000; Nishitsuji et al., 2009) nuclear import of vDNA (Gallay et al.,
1997; Tsurutani et al., 2000; Ikeda et al., 2004), and protein process-
ing during viral particle assembly and maturation (Mohammed
et al., 2011). Importantly, HIV-1 carrying point mutations at the
catalytic sites of IN (DDE) affected the integration step, but not
vDNA synthesis (Masuda et al., 1995). Thus, the pleiotropic effects
of IN mutations might not be directly related to the loss of its
catalytic function. These experiments suggest that IN may pos-
sess non-enzymatic roles throughout the viral replication cycle
(Figure 2).
Among the possible non-enzymatic roles of IN, there has been
an accumulation of evidence to suggest involvement of retro-
viral IN during reverse transcription (Engelman et al., 1995;
Masuda et al., 1995; Tsurutani et al., 2000; Lu et al., 2005; Dobard
et al., 2007). The contribution of IN during reverse transcrip-
tion has also been noticed in a retrovirus-like element of Sac-
charomyces cerevisiae, Ty3 (Nymark-McMahon and Sandmeyer,
1999; Nymark-McMahon et al., 2002). A previous study from
our laboratory showed that reverse transcription of HIV-1 was
abrogated by knocking down a host factor, survival motor neu-
ron (SMN)-interacting protein 1 (SIP1/Gemin2), which binds to
HIV-1 IN (Hamamoto et al., 2006). Gemin 2 is a component of
the SMN complex that mediates the assembly of spliceosomal
small nuclear ribonucleoproteins and nucleolar ribonucleopro-
teins (Fischer et al., 1997; Liu et al., 1997; Buhler et al., 1999;
Jablonka et al., 2001;Meister et al., 2001). In a subsequent study,we
demonstrated that HIV-1 IN andGemin2 synergistically stimulate
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FIGURE 2 | Non-enzymatic and enzymatic roles of HIV-1 IN that help
establish proviral DNA. After entry into cells, retroviral genomic RNA
(vRNA) is reverse transcribed into DNA (vDNA) by RT. Then, vDNA is
transported into the nucleus (nuclear import) and ﬁnally integrated into host
chromosomal DNA (black lines). IN forms a functional tetramer with vDNA
ends (intasome) to assist with integration. Subsequent repair processes by
host DNA repair machinery establishes the proviral DNA, in which retrovirus
DNA is stably integrated into host chromosomal DNA. IN tetramer
structures for its enzymatic (integration) and non-enzymatic functions
(reverse transcription and nuclear import) and possible involvement of host
factors are schematically depicted. The vRNA, vDNA, and host DNA are
shown as blue, red, and black lines, respectively. An arrowhead shows the
direction of each genome from the 5′- to the 3′-end.
RT activity by enhancing the assembly of RT on viral RNA in vitro
(Nishitsuji et al., 2009). Chow and colleagues have also reported
that HIV-1 IN stimulates RT activity through physical interactions
withRT (Zhu et al., 2004). Thus, INmight possess a direct function
to support efﬁcient reverse transcription by RT.
INSIGHT ON PUTATIVE STRUCTURE OF IN FOR ITS
NON-ENZYMATIC FUNCTION
Delineation of the IN mutant structure could provide clues for
depicting the IN conformation required for non-enzymatic func-
tions. Nuclear magnetic resonance (NMR) analysis of an isolated
NTD has shown that the NTD exists in two conformational states,
the E and D forms (Cai et al., 1997). A previous study using NMR
spectroscopy indicated that the NTDmutant protein, in which the
Tyr 15 residue was replaced with Ala (Y15A), folds correctly but
only as the E form (Nomura et al., 2006). The IN tetramer structure
was formed through interaction of NTD–CCD between the inner
subunits in the intasome (Hare et al., 2010). The residues 13–26
and 40–45 in the NTD interact extensively with residues 150–196
in the CCD of the other subunit. The importance of the NTD–
CCD interaction to form the IN tetramer has been proposed from
previous crystal structure analysis using the NTD–CCD IN frag-
ments (Wang et al., 2001; Hare et al., 2009b). As observed in these
previous analyses, the hydrogen-bond contacts between the side
chains of CCD residues Gln164 and Arg187 and the backbones
of the NTD residues Lys14 and Tyr15 also persist in the recent
structure-based model of the HIV-1 IN intasome (Krishnan et al.,
2010). HIV-1 carrying IN mutations at the Lys186, Arg187, and
Lys188 residues exhibited a reverse transcription-defective phe-
notype (Tsurutani et al., 2000) as found in the NTD mutants
including Y15A. These experimental data suggest that the func-
tional tetramer form, stabilized with the NTD–CCD interaction,
might be critical for the non-enzymatic function of IN during
reverse transcription.
IMPACT OF HOST FACTORS ON IN STRUCTURE AND
NON-ENZYMATIC FUNCTION
Numerous host factors that interact with HIV-1 IN have been
reported (Al-Mawsawi and Neamati, 2007). The best character-
ized factor is lens epithelium-derived growth factor/transcription
co-activator p75 (LEDGF/p75; Cherepanov et al., 2003) for chro-
mosomal targeting of HIV-1 IN (Maertens et al., 2003, 2004; Shun
et al., 2007). The crystal structure analysis of the PFV intasome
(Hare et al., 2010) together with results from previous studies (Li
et al., 2006; Hare et al., 2009a) suggest that synapsis formation
with DNA ends of the virus through tetramerization of IN might
be critical for proper assembly and/or a stable and functionally
active intasome. Importantly, LEDGF/p75 stabilizes the functional
tetramer of IN for its enzymatic function. Meanwhile, a reduction
of the tetramer form of IN was reproduced when wild-type IN
was expressed in cells in which endogenous Gemin2 was knocked
down byRNA interference (Nishitsuji et al., 2009).We also noticed
that the intracellular stability andmultimer formation of IN, espe-
cially the tetramer formation of IN, were dramatically reduced by
IN mutations that led to a reverse transcription-defective phe-
notype. Thus, in the absence of vDNA, host factors might be
involved in forming or maintaining highly ordered structures
of IN, which is critical for non-enzymatic function. Therefore,
inhibition of the interaction between IN and host factors could
be a novel therapeutic approach for the design and develop-
ment of new classes of IN inhibitors targeting non-enzymatic
functions.
CONCLUSION
It is obvious that IN must be closely associated with the viral
genome complex to form an active intasome upon the comple-
tion of reverse transcription. Physical interaction of IN with RT
(Zhu et al., 2004; Wilkinson et al., 2009) could contribute to
keeping IN close to the viral genome complex. How is the IN
structure in the absence of vDNA before and during reverse tran-
scription maintained? What is the contribution of host factors to
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IN conformation that is required for non-enzymatic functions?
The highly ordered IN structure and/or its interface structure
for interaction with host factors required for non-enzymatic IN
function(s) should be determined.
Finally, it should be emphasized that IN mutations affecting
non-enzymatic function resulted in severe deleterious affects to
HIV-1 replication compared with IN mutations that speciﬁcally
affected catalytic activity. Clinical efﬁcacy of the STI that blocks
IN catalytic activity guarantees that a greater impact on HIV-1
control would be achieved with a novel inhibitor that blocks the
non-enzymatic function of IN.
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